about
Recent advances in migraine therapyCGRP as a neuropeptide in migraine: lessons from miceCalcitonin gene-related peptide in the joint: contributions to pain and inflammationAnti-CGRP monoclonal antibodies in migraine: current perspectives.Migraine: multiple processes, complex pathophysiology.Development of anti-migraine therapeutics using the capsaicin-induced dermal blood flow model.The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis.The Role of the Paratrigeminal Nucleus in Vagal Afferent Evoked Respiratory Reflexes: A Neuroanatomical and Functional Study in Guinea PigsMeningeal blood flow is controlled by H2 S-NO crosstalk activating a HNO-TRPA1-CGRP signalling pathway.Activation of calcitonin gene-related peptide signaling through the prostaglandin E2-EP1/EP2/EP4 receptor pathway in synovium of knee osteoarthritis patients.Induction of Migraine-Like Photophobic Behavior in Mice by Both Peripheral and Central CGRP Mechanisms.Targeting CGRP: A New Era for Migraine Treatment.Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention.Nociceptor Sensory Neuron-Immune Interactions in Pain and Inflammation.From blast to bench: A translational mini-review of posttraumatic headache.Induction of calcitonin gene-related peptide expression in rats by cortical spreading depression.Treatment Update of Chronic Migraine.Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents.Plasmid pLXSN-Mediated Adrenomedullin Gene Therapy for Cerebral Vasospasm Following Subarachnoid Hemorrhage in Rats.Blocking CGRP in migraine patients - a review of pros and cons.Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.Human mast cells release the migraine-inducing factor pituitary adenylate cyclase-activating polypeptide (PACAP).Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study.Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.CGRP receptor activity in mice with global expression of human receptor activity modifying protein 1.Soluble guanylyl cyclase is a critical regulator of migraine-associated pain.Pituitary adenylate cyclase-activating polypeptide receptors in the trigeminovascular system: implications for migraine.Anatomy and immunochemical characterization of the non-arterial peptidergic diffuse dural innervation of the rat and Rhesus monkey: Implications for functional regulation and treatment in migraine.Diet-Induced Obesity Enhances TRPV1-Mediated Neurovascular Reactions in the Dura Mater.The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy.The α6 subunit-containing GABA receptor: A novel drug target for inhibition of trigeminal activation
P2860
Q26743537-5B0C2D30-19A8-458A-B0DE-CCB2E8F2EB5FQ26821821-FB3DD9E5-54EB-4C8C-936B-C55E19282209Q28081771-C94E3871-65DE-4F69-83B0-DDBA191A59BEQ34531880-65F843AB-8080-4518-806F-D79538EC91F2Q35547845-A6BD96C6-1B3F-44B7-94C0-4AAA54E1FA6BQ35675308-7C5D1DBB-EAF1-488D-BE84-BAB2213B78E5Q36340711-DB55313C-2928-4A0C-A513-2ED524F39375Q36387484-2719AB7D-D20D-4940-AEE8-2014C5D89B0CQ36506877-BDF8508D-ED33-4410-9934-A196A4C7170EQ37346133-EB486C1E-65F1-426E-AE6B-17E3802280C6Q37558868-BF7C69A6-62D0-42BF-9618-37E46EBB493BQ38542176-1F2B5544-2C2A-483F-8FED-A16723A67131Q38855312-D3E1ABC5-54EF-4B5B-B618-E8B471EF845FQ38994025-BECF19AA-92CE-4440-AC58-A2DCE7C6D5FFQ39115339-58D2DF87-7B1A-4E0E-9597-A6849F67362FQ39129824-FC30FB99-1956-4D26-B766-F8DE9A3335A5Q39251409-96D7AA3D-2116-40F3-A21C-2499FE50A5D9Q39748701-FE0400FB-0D23-4FA6-96C7-6F70335A71E1Q41035524-C4717DA5-4745-4227-AB9C-AEFC479DF024Q42363673-89A343BC-4DD2-492E-B3CF-1AEFC04FC581Q47095158-C34A0EE5-90D0-4472-AE25-ED63E9A5D8CDQ47441037-6CBCAF3A-5B4A-405B-86EC-BD44C5E8E157Q47663546-54262EAE-C867-4372-9C2D-C13E0D189C69Q47677099-4C00F616-A0A6-4539-BD5F-BB59F582ABC8Q47941983-1E247CF7-3965-45B0-B591-B02CA83E4AF9Q48023073-65FF0B65-01D0-410E-8A7D-992878F74194Q48034068-CE5D62FF-559F-4D8F-821F-9979424E51F1Q48932453-744BC45B-96A6-4B29-A423-38475453BF46Q51163764-EC0790C7-6FB4-46D5-9DA1-AE52D0DB9B8DQ52608146-8301C233-0948-4D9B-9245-3264B61BAC95Q57997641-F16F786F-5252-40F4-B804-BE0281C4D308
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Therapeutic antibodies against CGRP or its receptor
@ast
Therapeutic antibodies against CGRP or its receptor
@en
type
label
Therapeutic antibodies against CGRP or its receptor
@ast
Therapeutic antibodies against CGRP or its receptor
@en
prefLabel
Therapeutic antibodies against CGRP or its receptor
@ast
Therapeutic antibodies against CGRP or its receptor
@en
P2860
P356
P1476
Therapeutic antibodies against CGRP or its receptor
@en
P2093
Alan M Rapoport
Sarah Walter
P2860
P304
P356
10.1111/BCP.12591
P407
P577
2015-06-01T00:00:00Z